VivoSeq
Oncology

Breast Neoplasm

101

Pipeline Programs↗

1

Active Trials↗

46

Companies Involved↗

Breast Neoplasm is a highly competitive landscape with 101 programs across 46 companies. The most active players are Iovance Biotherapeutics, Inc., Syndax Pharmaceuticals, Bristol-Myers Squibb. 59 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

0/100

Mech. Concentration

8/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1S

Syndax Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2E

Eastern Cooperative Oncology Group

2 programs

Phase 2H

Hengrui Therapeutics, Inc.

1 program

Phase 2R

Risen (Suzhou) Pharma Tech Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical12

Cefazolin

Baxter Healthcare Corporation

Lapatinib

GSK

Clindamycin

Pfizer

Verteporfin

Bausch Health Americas, Inc.

Datopotamab Deruxtecan

Daiichi Sankyo

Phase 15

Aldesleukin

Iovance Biotherapeutics, Inc.

Entinostat

Syndax Pharmaceuticals

Disitamab Vedotin

Pfizer

Durvalumab

AstraZeneca

Camrelizumab

Sun Yat-sen University

Phase 218

Pyrotinib

Hengrui Therapeutics, Inc.

Ipatasertib

Roche

Ridaforolimus

Merck & Co.

Dalpiciclib

Risen (Suzhou) Pharma Tech Co., Ltd.

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Phase 37

Vinorelbine Tartrate

Gynecologic Oncology Group

Eribulin Mesylate

Eisai

Pembrolizumab

Merck & Co.

Avelumab

EMD Serono

Ketorolac

Javelin Pharmaceuticals

Approved59

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Talazoparib

Pfizer

Fulvestrant

Fresenius Kabi Oncology Ltd.

Propofol

Fresenius Kabi Oncology Ltd.

Venetoclax

AbbVie

Analysis

Modality Breakdown

84%

Small molecule

86 of 102 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody1212%Antibody–drug conjugate22%Protein / enzyme22%

Small molecule leads; the ring shows all 102 classified programs, each share of the total. Modality classified for 100% of 102 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
Completed·Pfizer logoPfizer·Phase 2·NCT00062751·108 enrolled
Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
Completed·EEnte Ospedaliero Ospedali Galliera·N/A·NCT06982313·1,545 enrolled
Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer
Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT01463072·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)